Five-Year ELIANA Follow-Up Shows Durable Remissions After Tisagenlecleucel
Five years after infusion, tisagenlecleucel is still holding a meaningful fraction of heavily pretreated children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia in remission. The updated ELIANA analysis extends the follow-up to a median of 79.4 months in 79 patients and gives one of the clearest long-range views yet of what a single autologous CD19-directed CAR-T infusion can accomplish in this age group.
The durability signal is not subtle. Among responders, estimated 5-year relapse-free survival reached 47.3% when censoring included subsequent anticancer therapy, including stem cell transplantation, and 51.0% when those later therapies were handled differently in the censoring framework. Overall survival followed a similar pattern, with a median that was not reached and estimated 5-year survival of 55.0% and 62.4% under the two censoring approaches. Those numbers sit in sharp contrast to the historically poor prognosis of pediatric and young adult patients whose leukemia has already returned or resisted prior therapy.
Survival Curves Keep Separating Long After Infusion
What matters clinically is the persistence of benefit over time rather than a short-lived remission spike. A therapy that can induce deep responses in this setting but loses momentum quickly would be of limited value for families and clinicians trying to avoid repeated cytotoxic salvage regimens. Here, the long tail of survival suggests that a substantial subgroup achieved biologic control of disease that lasted for years after a single infusion.
The analysis also reinforces an important feature of CAR-T therapy in B-ALL: remission durability cannot be interpreted without attention to postinfusion stem cell transplantation. Seventeen responders went on to receive a postinfusion SCT, and 14 of those transplants occurred while patients were still in complete remission. The fact that the reported survival estimates shift depending on whether later anticancer therapies are included in censoring shows how much real-world treatment sequencing can influence long-term interpretation. A single line of therapy may be functioning as definitive treatment in some patients, while in others it serves as a bridge to transplant.
B-Cell Recovery Remained Unresolved in the Long View
The median time to B-cell recovery was not reached when censoring for all further anticancer therapies, including SCT. In practical terms, prolonged B-cell aplasia remains one of the biologic signatures of sustained CAR-T activity, reflecting ongoing persistence or functional activity of the infused cells. For pediatric leukemia specialists, that matters because prolonged B-cell suppression is often used as an indirect marker that the engineered T-cell product continues to exert pressure on normal and malignant CD19-expressing B cells.
This long horizon also gives clinicians a clearer sense of how tisagenlecleucel behaves after the usual early toxicity and response window has passed. The central question is no longer whether the product can induce remission; it can. The question is how many patients can keep that remission without needing another line of therapy, another transplant, or another hospitalization for recurrent leukemia. The answer from this cohort is encouraging, though still incomplete.
Safety Stayed Stable Over Extended Follow-Up
No new or unexpected adverse events emerged during the 5-year analysis. That statement carries weight in a treatment class that initially raised concerns about cytokine release syndrome, neurologic toxicity, prolonged cytopenias, and late infectious complications. When a cellular therapy survives long-term follow-up without surfacing a fresh safety pattern, confidence rises that the long-term risk profile is dominated by known and monitorable issues rather than delayed surprises.
The absence of new late signals does not mean the treatment is trivial. It does mean the long-term conversation can move away from fear of unrecognized toxicity and toward patient selection, sequencing, and durability of disease control. For children and young adults with multiply relapsed B-ALL, a therapy with a single infusion and no unexpected late adverse event pattern offers a distinctly different proposition from repetitive chemotherapy blocks.
What the Data Say About Definitive Therapy in Heavily Pretreated ALL
This follow-up strengthens the case that tisagenlecleucel can function as definitive therapy for many patients with r/r B-ALL, not merely as a temporary remission strategy. The biologic logic is straightforward: CD19-directed CAR-T cells can eliminate residual leukemic clones that have survived prior chemotherapy, and in some patients that immune reset appears durable enough to hold the disease at bay for years. The long-term survival curves suggest that the treatment is not simply buying time; for a meaningful subset, it is changing the disease trajectory.
Even so, the cohort also shows that durability is not universal. Nearly half of responders still experienced an event by 5 years depending on how later therapy was counted, and some patients required transplant or other subsequent treatment. Those details matter because they frame CAR-T not as a uniform endpoint, but as a powerful tool whose long-term role may differ across patients with different disease biology, prior treatment exposure, and postinfusion course.
Long-Term Interpretation Depends on Censoring and Sequencing
The difference between analyses that include or exclude subsequent anticancer therapies is more than a statistical footnote. It reflects the reality that once patients enter the post-CAR-T period, later decisions can blur the boundary between treatment effect and treatment sequencing. A child who stays in remission for years without transplant tells a different clinical story from a child whose remission is consolidated with SCT. Both outcomes are important, but they do not represent the same therapeutic path.
The study’s long follow-up therefore does two things at once: it confirms that durable remission after a single infusion is possible, and it reminds clinicians that the post-CAR-T roadmap remains individualized. Some patients may truly be treated to a long-term plateau with tisagenlecleucel alone, while others still need additional intervention to secure that plateau.
The unanswered issue now is not whether the therapy can work, but which patients are most likely to remain among the long-term survivors, which should proceed to transplant, and how best to interpret late events when subsequent therapy enters the picture. Those questions will determine how widely this approach is used as a definitive strategy in pediatric and young adult leukemia care.